NLVP
ADAP

New Leaf Venture Partners’s Adaptimmune Therapeutics ADAP Stock Holding History

New Leaf Venture Partners’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-55,008
Closed -$388K – 16
2016
Q3 		$388K Sell
55,008
-72,033
-57% -$549K 0.28% 14
2016
Q2 		$1.03M Buy
+127,041
New +$1.2M 0.89% 13

Other funds holding ADAP

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

New Leaf Venture Partners's ADAP Position: Q4 2016 in Review

New Leaf Venture Partners sold out of Adaptimmune Therapeutics (ADAP) in Q4 2016, closing a stake of 55,008 shares — an estimated $388K sold.

New Leaf Venture Partners first reported a position in ADAP in Q2 2016 and held it in 2 quarters. The position peaked at $1.03M in Q2 2016. 40 funds tracked by Wall St. Rank hold ADAP as of Q4 2016.

  • New Leaf Venture Partners reported no remaining Adaptimmune Therapeutics position as of Q4 2016 after selling out during the quarter.
  • New Leaf Venture Partners sold 55,008 Adaptimmune Therapeutics shares in Q4 2016, an estimated $388K.
  • New Leaf Venture Partners first reported a position in Adaptimmune Therapeutics in Q2 2016 and held it in 2 quarters.
  • New Leaf Venture Partners's Adaptimmune Therapeutics position peaked at $1.03M in Q2 2016.
  • 40 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2016.

Based on New Leaf Venture Partners's 13F filing for Q4 2016, filed 14 Feb 2017.